Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of April 2003 and incorporates press releases dated April 14 and April 30, 2003. The financial data presented relates to the first quarter ended March 31, 2003. Compugen is a drug and diagnostic discovery company utilizing computational biology platforms to identify therapeutic targets and intellectual property.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenues | $2.575 million | $2.813 million |
| Net Loss | $2.338 million | $3.153 million |
| Net Loss Per Share | $(0.09) | $(0.12) |
| Cash and Equivalents (as of Mar 31, 2003) | $67.3 million | N/A |
| Operating Expenses | $5.616 million | $6.507 million |
As of March 31, 2003, total assets were $76.882 million, and total shareholders' equity was $66.640 million. The company reported a convertible loan of $1.714 million in long-term liabilities, which was not present in the prior year-end balance sheet.
Material Changes Versus Prior Period
- Revenue: Total revenues decreased by approximately 8.5% from $2.813 million in Q1 2002 to $2.575 million in Q1 2003. This decline was driven by a drop in product and service revenues from $2.350 million to $2.120 million, while R&D grants remained relatively stable ($463,000 vs. $455,000).
- Profitability: The net loss improved significantly, narrowing from $3.153 million in Q1 2002 to $2.338 million in Q1 2003. This improvement was primarily due to a reduction in total operating expenses from $6.507 million to $5.616 million.
- Expense Reduction: Significant decreases were observed in Sales and marketing expenses (down $312,000) and General and administrative expenses (down $351,000). Research and development expenses also decreased by $261,000.
- Liquidity: Cash, cash equivalents, and marketable securities remained stable at $67.3 million compared to December 31, 2002, including $1.7 million from a private placement by the subsidiary Evogene Ltd.
Guidance, Outlook, and Material Events
Scientific and Commercial Developments:
- VEGF114 Discovery: Compugen announced the discovery of VEGF114, a novel variant of the vascular endothelial growth factor gene, and received U.S. Patent No. 6,506,884. A nonexclusive license was granted to MultiGene Vascular Systems Ltd. (MGVS) for cardiovascular disease therapies. Compugen will receive an equity stake in MGVS and future royalties.
- Abbott Laboratories Agreement: An agreement was announced for Abbott to utilize Compugen's LEADS platform for drug target identification across multiple therapeutic areas.
- Diagnostic License: A license was granted to Diagnostic Products Corporation for assays based on novel prostate-specific proteins.
- Scientific Publication: The company published findings in Nature Biotechnology regarding the common occurrence of antisense RNA transcription.
Risks and Forward-Looking Statements:
The filing includes standard forward-looking statements regarding future events, noting risks such as changes in collaborator relationships, competitive products, technological changes, and the ability to retain customers. No specific financial guidance or revenue projections were provided in this filing.
Investor Verification Checklist
- Verify the terms and potential valuation of the equity stake received from MultiGene Vascular Systems Ltd.
- Confirm the commercial timeline and milestones for the Abbott Laboratories collaboration.
- Review the sustainability of the $455,000 in R&D grants included in revenue.
- Assess the impact of the new $1.714 million convertible loan on future debt obligations.
- Monitor the progress of the VEGF114 and PSA protein licensing deals for royalty generation.